共 50 条
Preventing diabetes complications
被引:3
|作者:
Templer, Sophie
[1
,2
]
Abdo, Sarah
[1
,3
]
Wong, Tang
[1
,2
,3
]
机构:
[1] Bankstown Lidcombe Hosp, Dept Endocrinol, Sydney, NSW, Australia
[2] Univ New South Wales, Fac Med, Sydney, NSW, Australia
[3] Western Sydney Univ, Sch Med, Sydney, NSW, Australia
关键词:
diabetes;
macrovascular complications;
microvascular complications;
cardiovascular disease;
glycaemic control;
INTENSIVE GLUCOSE CONTROL;
CARDIOVASCULAR OUTCOMES;
MICROVASCULAR OUTCOMES;
INSULIN-TREATMENT;
TYPE-2;
MORTALITY;
DISEASE;
METAANALYSIS;
MANAGEMENT;
MELLITUS;
D O I:
10.1111/imj.16455
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
The key aim of diabetes management is to prevent complications, which are a major cause of morbidity and mortality. At an individual level, people with diabetes are less likely than they were several decades ago to experience classical macrovascular and microvascular complications as a result of improvements in modifiable cardiovascular risk factors and preventive healthcare. However, a significant burden of diabetes complications persists at a population level because of the increasing incidence of diabetes, as well as longer lifetime exposure to diabetes because of younger diagnosis and increased life expectancy. Trials have shown that the most effective strategy for preventing complications of diabetes is a multifactorial approach focussing simultaneously on the management of diet, exercise, glucose levels, blood pressure and lipids. In addition to the cornerstone strategies of addressing diet, exercise and lifestyle measures, the introduction of newer glucose-lowering agents, including sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 agonists, have brought about a paradigm shift in preventing the onset and progression of complications of type 2 diabetes, particularly cardiovascular and renal disease. The improvement in rates of classical complications of diabetes over time has been accompanied by a growing awareness of non-traditional complications, including non-alcoholic fatty liver disease. These emerging complications may not respond to a glycaemic-centred approach alone and highlight the importance of foundational strategies centred on lifestyle measures and supported by pharmaceutical therapy to achieve weight loss and reduce metabolic risk in patients living with diabetes.
引用
收藏
页码:1264 / 1274
页数:11
相关论文